Pan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pan Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Peng Ji
Northwestern University, Chicago, Illinois, UNITED STATES
2 shared publications - Ermin Li
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL
1 shared publication - Honghao Bi
Department of Pathology, Feinberg School of Medicine and
1 shared publication - Inci Aydemir
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL
1 shared publication - Jing Yang
Department of Pathology, Feinberg School of Medicine, and
1 shared publication Kehan Ren
Department of Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States
1 shared publication
Latest Publications
- 5 September 2026
- Published by Elsevier
- Vol. 170, 325-344
Decoding the erythroid niche: From single-cell programs to spatially resolved architecture in mouse and human hematopoiesis
- 5 September 2026
- Published by Elsevier
- Vol. 170, 325-344
Decoding the erythroid niche: From single-cell programs to spatially resolved architecture in mouse and human hematopoiesis
- Open Access
- 8 May 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (13)
PPIL2 is a target of the JAK2/STAT5 pathway and promotes myeloproliferation via degradation of p53
The activated JAK2/STAT pathway is characteristic of myeloproliferative neoplasms (MPNs). The pleckstrin 2 (PLEK2) signalosome is downstream of the JAK2/STAT5 pathway and plays an important role in MPN development. The detailed molecular composition of this signalosome is unclear. Here, we reveal peptidylprolyl isomerase-like 2 (PPIL2) as a critical component of the complex in regulating human and murine erythropoiesis. PPIL2 was a direct target of STAT5 and was upregulated in patients with MPN and in a Jak2 V617F MPN mouse model. Mechanistically, PPIL2 interacted with and catalyzed p53 polyubiquitination and proteasome-mediated degradation to promote cell growth. Ppil2 deficiency, or inhibition by cyclosporin A, led to a marked upregulation of p53 in vivo and ameliorated myeloproliferative phenotypes in Jak2 V617F mice. Cyclosporin A also markedly reduced JAK2-mutated erythroid and myeloid proliferation in an induced pluripotent stem cell–derived human bone marrow organoid model. Our findings reveal PPIL2 as a critical component of the PLEK2 signalosome in driving MPN pathogenesis through negative regulation of p53, thus providing a target and opportunity for drug repurposing using cyclosporin A to treat MPNs.
- 8 May 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (13)
Open AccessPPIL2 is a target of the JAK2/STAT5 pathway and promotes myeloproliferation via degradation of p53
The activated JAK2/STAT pathway is characteristic of myeloproliferative neoplasms (MPNs). The pleckstrin 2 (PLEK2) signalosome is downstream of the JAK2/STAT5 pathway and plays an important role in MPN development. The detailed molecular composition of this signalosome is unclear. Here, we reveal peptidylprolyl isomerase-like 2 (PPIL2) as a critical component of the complex in regulating human and murine erythropoiesis. PPIL2 was a direct target of STAT5 and was upregulated in patients with MPN and in a Jak2 V617F MPN mouse model. Mechanistically, PPIL2 interacted with and catalyzed p53 polyubiquitination and proteasome-mediated degradation to promote cell growth. Ppil2 deficiency, or inhibition by cyclosporin A, led to a marked upregulation of p53 in vivo and ameliorated myeloproliferative phenotypes in Jak2 V617F mice. Cyclosporin A also markedly reduced JAK2-mutated erythroid and myeloid proliferation in an induced pluripotent stem cell–derived human bone marrow organoid model. Our findings reveal PPIL2 as a critical component of the PLEK2 signalosome in driving MPN pathogenesis through negative regulation of p53, thus providing a target and opportunity for drug repurposing using cyclosporin A to treat MPNs.